COMP gene coexpresses with EMT genes and is associated with poor survival in colon cancer patients

Valentine N Nfonsam, Landry E. Nfonsam, Debbie Chen, Pamela N. Omesiete, Alejandro Cruz, Raymond B. Runyan, Jana Jandova

Research output: Contribution to journalArticle

Abstract

Background: About 1.2 million new cases of colon cancer (CC) and 0.6 million deaths are reported every year, establishing CC as an important contributor to worldwide cancer morbidity and mortality. Although the overall incidence and mortality of CC have declined over the past 3 decades, the number of early-onset colon cancer ([EOCC], patients <50 y old) continues to rise alarmingly. These young patients are often diagnosed at a more advanced stage and tend to have poor survival. Our recently published data showed that the cartilage oligomeric matrix protein (COMP) is overexpressed in early-onset colon cancer patients. COMP is also reported in several cancers to coexpress with epithelial-mesenchymal transition (EMT) transcription factors. Given the role of EMT in cancer metastasis and cell invasion, we assessed the correlation between COMP gene expression and EMT gene expression in CC, and COMP's relationship to patient survival. Methods: mRNA expression of COMP was compared to that of EMT markers using the UCSC Cancer Genomics Browser. Survival analysis was performed using the UCSC Xena Browser for cancer genomics. Results: Expression analysis revealed coexpression of COMP with the EMT markers CDH2, FN1, VIM, TWIST1, TWIST2, SNAI1, SNAI2, ZEB1, ZEB2, POSTN, MMP2, MMP9, and COL1A1. Samples that were more mesenchymal had higher expression levels of COMP and EMT markers, thus suggesting a potential role of COMP in EMT. Patients with increased COMP expression presented with poorer overall survival compared to patients with no change or reduced COMP expression (P = 0.02). Conclusions: These findings reveal COMP as a potential biomarker for CC especially in more aggressive CC and CC in young patients, with a likely role in EMT during tumor metastasis and invasion, and a contributing factor to patient survival.

LanguageEnglish (US)
Pages297-303
Number of pages7
JournalJournal of Surgical Research
Volume233
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cartilage Oligomeric Matrix Protein
Epithelial-Mesenchymal Transition
Colonic Neoplasms
Survival
Genes
Neoplasms
Genomics
Neoplasm Metastasis
Gene Expression
Mortality
Survival Analysis
Transcription Factors
Biomarkers

Keywords

  • Cartilage oligomeric matrix protein
  • Colon cancer
  • COMP
  • EMT
  • Epithelial-mesenchymal transition
  • Survival

ASJC Scopus subject areas

  • Surgery

Cite this

COMP gene coexpresses with EMT genes and is associated with poor survival in colon cancer patients. / Nfonsam, Valentine N; Nfonsam, Landry E.; Chen, Debbie; Omesiete, Pamela N.; Cruz, Alejandro; Runyan, Raymond B.; Jandova, Jana.

In: Journal of Surgical Research, Vol. 233, 01.01.2019, p. 297-303.

Research output: Contribution to journalArticle

Nfonsam, Valentine N ; Nfonsam, Landry E. ; Chen, Debbie ; Omesiete, Pamela N. ; Cruz, Alejandro ; Runyan, Raymond B. ; Jandova, Jana. / COMP gene coexpresses with EMT genes and is associated with poor survival in colon cancer patients. In: Journal of Surgical Research. 2019 ; Vol. 233. pp. 297-303.
@article{805eeaedc4d54ec287d210207d19bb6e,
title = "COMP gene coexpresses with EMT genes and is associated with poor survival in colon cancer patients",
abstract = "Background: About 1.2 million new cases of colon cancer (CC) and 0.6 million deaths are reported every year, establishing CC as an important contributor to worldwide cancer morbidity and mortality. Although the overall incidence and mortality of CC have declined over the past 3 decades, the number of early-onset colon cancer ([EOCC], patients <50 y old) continues to rise alarmingly. These young patients are often diagnosed at a more advanced stage and tend to have poor survival. Our recently published data showed that the cartilage oligomeric matrix protein (COMP) is overexpressed in early-onset colon cancer patients. COMP is also reported in several cancers to coexpress with epithelial-mesenchymal transition (EMT) transcription factors. Given the role of EMT in cancer metastasis and cell invasion, we assessed the correlation between COMP gene expression and EMT gene expression in CC, and COMP's relationship to patient survival. Methods: mRNA expression of COMP was compared to that of EMT markers using the UCSC Cancer Genomics Browser. Survival analysis was performed using the UCSC Xena Browser for cancer genomics. Results: Expression analysis revealed coexpression of COMP with the EMT markers CDH2, FN1, VIM, TWIST1, TWIST2, SNAI1, SNAI2, ZEB1, ZEB2, POSTN, MMP2, MMP9, and COL1A1. Samples that were more mesenchymal had higher expression levels of COMP and EMT markers, thus suggesting a potential role of COMP in EMT. Patients with increased COMP expression presented with poorer overall survival compared to patients with no change or reduced COMP expression (P = 0.02). Conclusions: These findings reveal COMP as a potential biomarker for CC especially in more aggressive CC and CC in young patients, with a likely role in EMT during tumor metastasis and invasion, and a contributing factor to patient survival.",
keywords = "Cartilage oligomeric matrix protein, Colon cancer, COMP, EMT, Epithelial-mesenchymal transition, Survival",
author = "Nfonsam, {Valentine N} and Nfonsam, {Landry E.} and Debbie Chen and Omesiete, {Pamela N.} and Alejandro Cruz and Runyan, {Raymond B.} and Jana Jandova",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jss.2018.08.021",
language = "English (US)",
volume = "233",
pages = "297--303",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - COMP gene coexpresses with EMT genes and is associated with poor survival in colon cancer patients

AU - Nfonsam, Valentine N

AU - Nfonsam, Landry E.

AU - Chen, Debbie

AU - Omesiete, Pamela N.

AU - Cruz, Alejandro

AU - Runyan, Raymond B.

AU - Jandova, Jana

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: About 1.2 million new cases of colon cancer (CC) and 0.6 million deaths are reported every year, establishing CC as an important contributor to worldwide cancer morbidity and mortality. Although the overall incidence and mortality of CC have declined over the past 3 decades, the number of early-onset colon cancer ([EOCC], patients <50 y old) continues to rise alarmingly. These young patients are often diagnosed at a more advanced stage and tend to have poor survival. Our recently published data showed that the cartilage oligomeric matrix protein (COMP) is overexpressed in early-onset colon cancer patients. COMP is also reported in several cancers to coexpress with epithelial-mesenchymal transition (EMT) transcription factors. Given the role of EMT in cancer metastasis and cell invasion, we assessed the correlation between COMP gene expression and EMT gene expression in CC, and COMP's relationship to patient survival. Methods: mRNA expression of COMP was compared to that of EMT markers using the UCSC Cancer Genomics Browser. Survival analysis was performed using the UCSC Xena Browser for cancer genomics. Results: Expression analysis revealed coexpression of COMP with the EMT markers CDH2, FN1, VIM, TWIST1, TWIST2, SNAI1, SNAI2, ZEB1, ZEB2, POSTN, MMP2, MMP9, and COL1A1. Samples that were more mesenchymal had higher expression levels of COMP and EMT markers, thus suggesting a potential role of COMP in EMT. Patients with increased COMP expression presented with poorer overall survival compared to patients with no change or reduced COMP expression (P = 0.02). Conclusions: These findings reveal COMP as a potential biomarker for CC especially in more aggressive CC and CC in young patients, with a likely role in EMT during tumor metastasis and invasion, and a contributing factor to patient survival.

AB - Background: About 1.2 million new cases of colon cancer (CC) and 0.6 million deaths are reported every year, establishing CC as an important contributor to worldwide cancer morbidity and mortality. Although the overall incidence and mortality of CC have declined over the past 3 decades, the number of early-onset colon cancer ([EOCC], patients <50 y old) continues to rise alarmingly. These young patients are often diagnosed at a more advanced stage and tend to have poor survival. Our recently published data showed that the cartilage oligomeric matrix protein (COMP) is overexpressed in early-onset colon cancer patients. COMP is also reported in several cancers to coexpress with epithelial-mesenchymal transition (EMT) transcription factors. Given the role of EMT in cancer metastasis and cell invasion, we assessed the correlation between COMP gene expression and EMT gene expression in CC, and COMP's relationship to patient survival. Methods: mRNA expression of COMP was compared to that of EMT markers using the UCSC Cancer Genomics Browser. Survival analysis was performed using the UCSC Xena Browser for cancer genomics. Results: Expression analysis revealed coexpression of COMP with the EMT markers CDH2, FN1, VIM, TWIST1, TWIST2, SNAI1, SNAI2, ZEB1, ZEB2, POSTN, MMP2, MMP9, and COL1A1. Samples that were more mesenchymal had higher expression levels of COMP and EMT markers, thus suggesting a potential role of COMP in EMT. Patients with increased COMP expression presented with poorer overall survival compared to patients with no change or reduced COMP expression (P = 0.02). Conclusions: These findings reveal COMP as a potential biomarker for CC especially in more aggressive CC and CC in young patients, with a likely role in EMT during tumor metastasis and invasion, and a contributing factor to patient survival.

KW - Cartilage oligomeric matrix protein

KW - Colon cancer

KW - COMP

KW - EMT

KW - Epithelial-mesenchymal transition

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85052904100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052904100&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2018.08.021

DO - 10.1016/j.jss.2018.08.021

M3 - Article

VL - 233

SP - 297

EP - 303

JO - Journal of Surgical Research

T2 - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

ER -